Page 138 - 《中国药房》2023年13期

[ 8 ] GERMOVSEK E，LUTSAR I，KIPPER K，et al. Plasma 呼吸杂志，2018，41（6）：409-446.
and CSF pharmacokinetics of meropenem in neonates and [21] SILVA M A，DIAS G，CARDOSO T. Correlation of esti‐
young infants：results from the NeoMero studies[J]. J Anti‐ mated creatinine clearance and glomerular filtration rate
microb Chemother，2018，73（7）：1908-1916. in very elderly patients and antibiotic prescribing errors：
[ 9 ] AL-SHAER M H，ALGHAMDI W A，GRAHAM E，et al. cohort study [J]. Acta Med Port，2021，34（5）：335-341.
Meropenem，cefepime，and piperacillin protein binding in [22] HASSANPOUR R，ZIAIE S，KOBARFARD F，et al.
patient samples[J]. Ther Drug Monit，2020，42（1）：129-132. Evaluation of pharmacokinetic and pharmacodynamic pa‐
[10] CONTEJEAN A，JAFFRELOT L，BENABOUD S，et al. rameters of meropenem in critically ill patients with acute
A meropenem pharmacokinetics model in patients with kidney disease[J]. Eur J Clin Pharmacol，2021，77（6）：
haematological malignancies[J]. J Antimicrob Chemother， 831-840.
2020，75（10）：2960-2968. [23] CHAIJAMORN W，RUNGKITWATTANAKUL D，
[11] OSHIMA K，NAKAMURA S，IWANAGA N，et al. Effi‐ PATTHARACHAYAKUL S，et al. Meropenem dosing
cacy of high-dose meropenem （six grams per day） in recommendations for critically ill patients receiving con‐
treatment of experimental murine pneumonia induced by tinuous renal replacement therapy[J]. J Crit Care，2020，
meropenem-resistant Pseudomonas aeruginosa[J]. Antimi‐ 60：285-289.
crob Agents Chemother，2017，61（1）：e02056-e02016. [24] ALMULHIM A S，AL-DAHNEEN B A，ALSOWAIDA Y S.
[12] BENÍTEZ-CANO A，LUQUE S，SORLÍ L，et al. Intrapul‐ Pharmacists’ knowledge about the impact of augmented
monary concentrations of meropenem administered by renal clearance on antimicrobial dosing in critically ill
continuous infusion in critically ill patients with nosoco‐ patients：a cross-sectional study[J]. Infect Dis Ther，2020，
mial pneumonia：a randomized pharmacokinetic trial[J]. 9（3）：599-608.
Crit Care，2020，24（1）：55. [25] RAZZAZZADEH S，DARAZAM I A，HAJIESMAEILI
[13] HOSMANN A，RITSCHER L，BURGMANN H，et al. M，et al. Investigation of pharmacokinetic and clinical out‐
Meropenem concentrations in brain tissue of neurointen‐ comes of various meropenem regimens in patients with
sive care patients exceed CSF levels[J]. J Antimicrob Che‐ ventilator-associated pneumonia and augmented renal
mother，2021，76（11）：2914-2922. clearance[J]. Eur J Clin Pharmacol，2022，78（5）：823-829.
[14] OHATA Y，TOMITA Y，SUNAKAWA K，et al. Cerebro‐ [26] LEE D H，KIM H S，PARK S，et al. Population pharmaco‐
spinal pharmacokinetic and pharmacodynamic analysis of kinetics of meropenem in critically ill Korean patients and
efficacy of meropenem in paediatric patients with bacte‐ effects of extracorporeal membrane oxygenation[J]. Phar‐
rial meningitis[J]. Int J Antimicrob Agents，2019，54（3）： maceutics，2021，13（11）：1861.
292-300. [27] TAMATSUKURI T，OHBAYASHI M，KOHYAMA N，et
[15] KONIG C，GRENSEMANN J，CZORLICH P，et al. A al. The exploration of population pharmacokinetic model
dosing nomograph for cerebrospinal fluid penetration of for meropenem in augmented renal clearance and investi‐
meropenem applied by continuous infusion in patients gation of optimum setting of dose[J]. J Infect Chemother，
with nosocomial ventriculitis[J/OL]. 2022[2023-03-27]. 2018，24（10）：834-840.
https：//www. ncbi. nlm. nih. gov/pubmed/35182756. DOI： [28] SELIG D J，AKERS K S，CHUNG K K，et al. Merope‐
10.1016/j.cmi.2022.02.017. nem pharmacokinetics in critically ill patients with or
[16] MOON Y S，CHUNG K C，GILL M A. Pharmacokinetics without burn treated with or without continuous veno-
of meropenem in animals，healthy volunteers，and patients venous haemofiltration[J]. Br J Clin Pharmacol，2022，88
[J]. Clin Infect Dis，1997，24（Suppl 2）：S249-S255. （5）：2156-2168.
[17] IKAWA K，KONDO N，NAKASHIMA A，et al. Penetra‐ [29] BASTIDA C，HERNÁNDEZ-TEJERO M，AZIZ F，et al.
tion of meropenem into human pancreatic juice[J]. Scand Meropenem population pharmacokinetics in patients with
J Infect Dis，2013，45（5）：404-406. decompensated cirrhosis and severe infections[J]. J Anti‐
[18] GANGULY S，EDGINTON A N，GERHART J G，et al. microb Chemother，2020，75（12）：3619-3624.
Physiologically based pharmacokinetic modeling of me‐ [30] GRENSEMANN J，BUSSE D，KÖNIG C，et al. Acute-on-
ropenem in preterm and term infants[J]. Clin Pharmacoki‐ chronic liver failure alters meropenem pharmacokinetics
net，2021，60（12）：1591-1604. in critically ill patients with continuous hemodialysis：an
[19] RAPP M，URIEN S，FOISSAC F，et al. Population phar‐ observational study[J]. Ann Intensive Care，2020，10（1）：48.
macokinetics of meropenem in critically ill children with [31] PIANO S，SINGH V，CARACENI P，et al. Epidemiology
different renal functions[J]. Eur J Clin Pharmacol，2020， and effects of bacterial infections in patients with cirrhosis
76（1）：61-71. worldwide[J]. Gastroenterology，2019，156（5）：1368-1380.
[20] 中国医药教育协会感染疾病专业委员会. 抗菌药物药代 （收稿日期：2022-11-11 修回日期：2023-03-31）
动力学/药效学理论临床应用专家共识[J]. 中华结核和 （编辑：唐晓莲）

· 1664 · China Pharmacy 2023 Vol. 34 No. 13 中国药房 2023年第34卷第13期